Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Peptide or peptide-derivative label; see identity
Supplied sequence or chemical reference
Mechanism
Bioregulator associated in literature with KE dipeptide; confirm the commercial product matches that identity.
Evidence and critical reading
Reported scientific and empirical uses
Aging research · Immune modulation and inflammation
Immune/aging narrative; cell gene expression does not demonstrate extended human life.
Human evidence
The located study assessed SIRT1/PARP expression/protein synthesis in human mesenchymal stem cells. It was not a patient longevity/immune-treatment trial.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
The located study assessed SIRT1/PARP expression/protein synthesis in human mesenchymal stem cells. It was not a patient longevity/immune-treatment trial.
The located study assessed SIRT1/PARP expression/protein synthesis in human mesenchymal stem cells. It was not a patient longevity/immune-treatment trial.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Human-study exposure
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Empirical handbook
No numerical human dose is assigned: reviewed sources did not verify a regimen attributable to this material, route and indication. Other molecules’ doses, animal exposures, vial amounts and dietary requirements are not substituted.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
No human regimen or interaction profile of the commercial identity was verified; do not extrapolate generic bioregulator doses.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
No selected studies are attributed in this record.
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Vilon · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID37782636
Khavinson VK, Linkova NS, Ashapkin VV, Shilovsky GA, Borushko NV, Petukhov MG, Vanuyshin BF.
October 16, 2026
- SEARCH-PUBMED-vilon
PubMed/MED targeted search: TITLE_ABS:vilon AND TITLE_ABS:peptide
October 16, 2026